Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

November 18, 2020November 18, 2020

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

News

The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy ... Read more

November 16, 2020November 16, 2020

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

News

The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people ... Read more

November 11, 2020November 11, 2020

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

News

An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy ... Read more

October 28, 2020October 28, 2020

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

News

A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific ... Read more

October 7, 2020October 12, 2020

Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial

News

Note: This story was updated Oct. 12, 2020, to note that semorinemab is intended to target phosphorylated and non-phosphorylated forms of tau. Semorinemab, a monoclonal antibody against tau, failed ... Read more

September 14, 2020September 14, 2020

Phase 3 Trial of AXS-05 to Treat Agitation in Alzheimer’s Likely by Year’s End

News

Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed ... Read more

August 26, 2020August 26, 2020

Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says

News

People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at ... Read more

June 3, 2020June 3, 2020

Mouth Bacteria Can Infect Brain Cells, Research Finds, Supporting Alzheimer’s Link

News

A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The infection results in cellular changes that are similar to ... Read more

May 18, 2020May 18, 2020

PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

News

Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from ... Read more

May 4, 2020May 4, 2020

Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

News

Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a ... Read more